We analyzed NFD by immunohistochemistry in different brains areas from genetic FTLD-Tau (3 different mutations) and AD patients (at different Braak stages) using either conformation-dependent or phospho-dependent antibodies. This evidence concerns the gene MAPT and Alzheimer disease.